Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

Stock Information for Cosmos Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cosmos Health Inc.

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
Cosmos Health is Forcing the Market to Reframe the Conversation
Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets
Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M
Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.